Suchergebnisse - (Standardsuche:ritonavir)

PubPharm (247)

21

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials

enthalten in: Aids | 2015

von Raffi, F. | Rachlis, A. | Brinson, C. | +10

22

Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women

enthalten in: Aids | 2015

von Cohan, D. | Natureeba, P. | Koss, C. | +12

23

Acute interstitial nephritis caused by lopinavir/ritonavir in a surgeon receiving antiretroviral postexposure prophylaxis

enthalten in: Aids | 2015

von Chughlay, M. | Njuguna, C. | Cohen, K. | +1

24

Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age

enthalten in: Aids | 2015

von Ciaranello, A. | Doherty, K. | Penazzato, M. | +12

25

Renal tubular disease in the era of combination antiretroviral therapy

enthalten in: Aids | 2015

von Hamzah, L. | Booth, J. | Jose, S. | +8

26

Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues

enthalten in: Aids | 2015

von Antinori, A. | Clarke, A. | Svedhem-Johansson, V. | +10

27

Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease

enthalten in: Aids | 2015

von Casadellà, M. | Manzardo, C. | Noguera-Julian, M. | +9

28

Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa

enthalten in: Aids | 2015

von Ciaffi, L. | Koulla-Shiro, S. | Sawadogo, A. | +9

29

Protease inhibitors exposure is not related to lung cancer risk in HIV smoker patients: a nested case-control study

enthalten in: Aids | 2015

von Bruyand, M. | Le Marec, F. | Lavole, A. | +8

30

Choice of effect measure in HIV randomized trials

enthalten in: Aids | 2015

von Flandre, P.